Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIb: Double-Blind, Randomized, Placebo Controlled, Dose-ranging Trial of BMS-927711 for the Acute Treatment of Migraine

NCT01430442 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01430442
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01430442 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIb: Double-Blind, Randomized, Placebo Controlled, Dose-ranging Trial of BMS-927711 for the Acute Treatment of Migraine
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2011
Completion date
May 31, 2012
Enrollment
1,026 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

acute treatment of migraine, migraine